Compare Essex Property Trust, Inc. (ESS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Essex Property Trust, Inc. trades at $268.84 (market cap $17.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Essex Property Trust, Inc. is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Essex Property Trust, Inc. pays a 3.85% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 112 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ESS | SYRE | |
|---|---|---|
Market Cap | $17.31B | $7.35B |
Volume | 358,204 | 1,624,631 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $108.92 |
52-Week Low | $239.61 | $22.18 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $23.91B | $6.35B |
Dividend Yield | 3.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $271.88, up 0.55% with neutral technical signals. The company reported mixed Q2 2026 results, beating FFO guidance but missing EPS estimates. Strong operational efficiency is evident with 67.9% gross margins and $1.07B operating cash flow. Recent developments include conference presentations and dividend declarations, while legal settlements have reduced risk overhangs. Analyst consensus shows a $300.77 price target with 38% buy ratings.
ESS demonstrates solid fundamentals with revenue growth to $1.89B and robust profitability, though elevated P/E of 41.96 suggests premium valuation. Upside potential exists from raised 2026 guidance and institutional accumulation, but risks include debt levels at $6.46B and regional real estate exposure. The stock offers income via $2.59 dividend amid cautious analyst sentiment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
